Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

References

• LeporeMPampanelliSFanelliCPharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lisproDiabetes2000492142 214811118018
   PubMed Web of Science ®Google Scholar
• HeiseTTackCJCuddihyRA new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialDiabetes Care201134669 67421285389
   PubMed Web of Science ®Google Scholar
• HorvathKJeitlerKBergholdALong-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusCochrane Database Syst Rev20072CD00561317443605
   PubMed Web of Science ®Google Scholar
• InzucchiSilvio EBergenstalRichard MBuseJohn B2015Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care381140 14925538310
   PubMed Web of Science ®Google Scholar
• WakilAAtkinSLEfficacy and safety of ultra-long-acting insulin degludecTher Adv Endocrinol Metab2012355 5923148194
   PubMedGoogle Scholar
• JonassenIHavelundSHoeg-JensenTSteensgaardDBWahlundP-ORibelUDesign of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulinPharm Res2012292104 211422485010
   PubMed Web of Science ®Google Scholar
• HaahrHHeiseTA review of the pharmacological properties of insulin degludec and their clinical relevanceClin Pharmacokinet201453787 80025179915
   PubMed Web of Science ®Google Scholar
• HeiseTHermanskiLNosekLFeldmanARasmussenSHaahrHInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetesDiabetes Obes Metab201214859 86422594461
   PubMed Web of Science ®Google Scholar
• BiesterTBlaesigSRemusKInsulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes: insulin degludec in children/adolescentsPediatr Diabetes20141527 3324467565
   PubMed Web of Science ®Google Scholar
• KorsatkoSDellerSMaderJKUltra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitusDrugs Aging20143147 5324263619
   PubMed Web of Science ®Google Scholar
• KissIAroldGRoepstorffCBøttcherSGKlimSHaahrHInsulin degludec: pharmacokinetics in patients with renal impairmentClin Pharmacokinet201453175 18324163264
   PubMed Web of Science ®Google Scholar
• KupčováVAroldGRoepstorffCHøjbjerreMKlimSHaahrHInsulin degludec: pharmacokinetic properties in subjects with hepatic impairmentClin Drug Investig201434127 133
   PubMed Web of Science ®Google Scholar
• ZinmanBPhilis-TsimikasACariouBInsulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Diabetes Care2012352464 247123043166
   PubMed Web of Science ®Google Scholar
• RodbardHWCariouBZinmanBComparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized, treat-to-target trialDiabet Med2013301298 130423952326
   PubMed Web of Science ®Google Scholar
• OnishiYIwamotoYYooSJClausonPTamerSCParkSInsulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trialJ Diabetes Investig20134605 612
   PubMed Web of Science ®Google Scholar
• GarberAJKingABPratoSDInsulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target noninferiority trialLancet20123791498 150722521072
   PubMed Web of Science ®Google Scholar
• MeneghiniLAtkinSLGoughSCLThe efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetesDiabetes Care201336858 86423340894
   PubMed Web of Science ®Google Scholar
• HollanderPKingABDel PratoSInsulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapyDiabetes Obes Metab201517202 20625387855
   PubMed Web of Science ®Google Scholar
• RatnerREGoughSCLMathieuCHypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trialsDiabetes Obes Metab201315175 18423130654
   PubMed Web of Science ®Google Scholar
• ZinmanBDeVriesJHBodeBEfficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsLancet Diabetes Endocrinol20131123 13124622318
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasABrodMNiemeyerMOcampo FranciscoAMRothmanJInsulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: Once Simple Use)Adv Ther201330607 62223812875
   PubMed Web of Science ®Google Scholar
• OnishiYOnoYRabølREndahlLNakamuraSSuperior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trialDiabetes Obes Metab201315826 83223557077
   PubMed Web of Science ®Google Scholar
• KanekoSChowFChoiDSInsulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trialDiabetes Res Clin Pract2015107139 14725498130
   PubMed Web of Science ®Google Scholar
• FulcherGRChristiansenJSBantwalGComparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a Phase 3a, randomized, treat-to-target trialDiabetes Care2014372084 209024812432
   PubMed Web of Science ®Google Scholar
• MeierJJGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNat Rev Endocrinol20128728 74222945360
   PubMed Web of Science ®Google Scholar
• GoughSCBodeBWooVEfficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetesLancet Diabetes Endocrinol20142885 89325190523
   PubMed Web of Science ®Google Scholar
• BuseJBVilsbollTThurmanJContribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)Diabetes Care2014372926 293325114296
   PubMed Web of Science ®Google Scholar
• MathieuCRodbardHWCariouBA comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)Diabetes Obes Metab201416636 64424443830
   PubMed Web of Science ®Google Scholar
• GoughSCLBhargavaAJainRMersebachHRasmussenSBergenstalRMLow-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trialDiabetes Care2013362536 254223715753
   PubMed Web of Science ®Google Scholar
• BodeBWChaykinLBSussmanAMEfficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (Begin: Compare)Endocr Pract201420785 79124518180
   PubMed Web of Science ®Google Scholar
• EvansMKhuntiKMamdaniMHealth-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countriesHealth Qual Life Outcomes2013119023731777
   PubMed Web of Science ®Google Scholar
• FreemantleNEvansMChristensenTWoldenMLBjornerJBA comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trialsDiabetes Obes Metab201315564 57123451759
   PubMed Web of Science ®Google Scholar
• HemkensLGGrouvenUBenderRRisk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia2009521732 174419565214
   PubMed Web of Science ®Google Scholar
• ColhounHMSDRN Epidemiology GroupUse of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia2009521755 176519603149
   PubMed Web of Science ®Google Scholar
• FagotJ-PBlotiereP-ORicordeauPWeillAAllaFAllemandHDoes insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databasesDiabetes Care201336294 30122966091
   PubMed Web of Science ®Google Scholar
• KurtzhalsPSchäfferLSørensenACorrelations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical useDiabetes200049999 100510866053
   PubMed Web of Science ®Google Scholar
• AginAJeandidierNGasserFGruckerDSapinRGlargine blood biotransformation: in vitro appraisal with human insulin immunoassayDiabetes Metab200733205 21217360218
   PubMed Web of Science ®Google Scholar
• NishimuraESorensenARHansenBFInsulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potentialDiabetologia201053Suppl 1S388 Abstr 974
   Google Scholar